NuProbe Global is a genomics and molecular diagnostics company with sites in Houston, TX, Shanghai, and Suzhou. The company develops molecular diagnostic technologies that improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. NuProbe is led by CEO Yingshuang Chai and co-founder David Zhang, who is also CEO of NuProbe USA. The company raised $50M in funding to support its growth. Proceeds will be used to expand commercial operations, accelerate IVD product clinical studies and regulatory submissions, and develop new genomics and molecular diagnostics technologies. Since its last fundraising in 2021, NuProbe has engaged in research collaborations with several multinational companies and clinical collaborations with over 400 hospitals. NuProbe develops molecular diagnostic technologies and ultrasensitive NGS panels that it says improve detection of sequencing mutations and copy number variations by over 10-fold. The company has signed partnership and licensing deals with Illumina, Qiagen, Oxford Nanopore and the Wego Group, and has begun partnering with pharma companies for clinical research using its Augury™ custom NGS panels. In China’s reproductive health market NuProbe has built collaborations with most top hospitals and is described as a leader in infertility testing. Led by co-founder and CEO Yingshuang Chai, the team includes co-founder and Head of Innovation David Zhang and a scientific advisory board featuring David Walt and George Church. NuProbe operates out of Houston (USA), Shanghai and Suzhou (China). The company plans to expand its commercial teams in the US and China, develop new NGS products, and pursue regulatory approval in China for its clinical products. NuProbe develops toehold probe–based molecular diagnostics technology licensed from Harvard’s Wyss Institute and Rice University to enable highly sensitive, multiplexed detection of disease signatures in cell-free DNA. Its core product focus is on ultra-sensitive, non-invasive blood tests for early cancer detection, infectious disease, and other genomics applications, with platforms intended for cancer, NIPT, and infectious-disease diagnostics. In pre-clinical work the technology improved qPCR and NGS mutation detection sensitivity by 10–100×, achieving limits of detection down to 0.01% and demonstrating multiplexing of 10–100 reactions capable of detecting hundreds of mutations. The proprietary assays are compatible with common PCR and sequencing workflows, which the company says supports clinical applicability. NuProbe plans to use new funding to grow staff in its Cambridge, Mass. and China offices and to continue technology development, clinical trials, and commercialization efforts. Financially, the company recently completed an $11 million Series A to support these development and go-to-market activities.

Total raised

$103M

Funding rounds

3

Latest round

Equity

Latest activity

Jun 2022